Insights from the RedirecTT-1 Study: A Potential Game-Changer for R/R Myeloma with EMD
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Insights from the RedirecTT-1 Study: A Potential Game-Changer for R/R Myeloma with EMD
-
Narrated by:
-
Written by:
About this listen
Shahzad Raza, MD, Hematologist at Cleveland Clinic, joins the Cancer Advances podcast to share insights from the RedirecTT-1 study. This study, presented at the 2025 American Society of Hematology (ASH) Annual Meeting, explores combining two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed/refractory multiple myeloma with extramedullary disease. Listen as Dr. Raza discusses disease biology, outcomes, safety considerations and why this approach could be a major step forward for high-risk myeloma care.
No reviews yet